Silence-Intradigm Deal is Only Year-End Noise on Quiet RNAi Front
This article was originally published in The Pink Sheet Daily
Executive Summary
The only RNAi-focused merger of the year so far weds two minor players trying to build a much-needed drug delivery platform.
You may also be interested in...
Venture-Backed Dicerna Cuts First Pharma Deal With Kyowa Hakko Kirin As Prelude to 'B' Round
As it looks for a new investor to lead its second round of funding, RNA interference start-up Dicerna Pharmaceuticals has signed its first big-pharma customer. Japan's Kyowa Hakko Kirin will pay $4 million up-front and as much as $120 million in milestones to develop therapeutics around an undisclosed solid-tumor cancer target using Dicerna's technology
Venture-Backed Dicerna Cuts First Pharma Deal as Prelude to 'B' Round
The startup takes preclinical money from Kyowa Hakko Kirin to target cancer with its alternative RNAi method.
Venture-Backed Dicerna Cuts First Pharma Deal as Prelude to 'B' Round
The startup takes preclinical money from Kyowa Hakko Kirin to target cancer with its alternative RNAi method.